
|Videos|July 15, 2019
TRK Inhibitors: A Tumor Agnostic Approach to Treatment of Solid Tumors
General Cancer
Advertisement
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Rezatapopt Shows 46% ORR in TP53 Y220C–Mutated Ovarian Cancer
2
Daraxonrasib Shows Antitumor Activity in RAS-Mutant NSCLC
3
First-Line Savolitinib/Osimertinib Improves PFS in MET+ NSCLC
4
G2032R Resistance Data Is Reshaping Second-Line Sequencing in ROS1+ NSCLC
5































